Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Am J Gastroenterol. 2020 Jun;115(6):885–894. doi: 10.14309/ajg.0000000000000596

Figure 2:

Figure 2:

Figure 2:

Incremental value of fecal calprotectin≥250μg/g in different clinical scenarios in predicting the presence of moderate to severe endoscopic activity, (A) after induction therapy and (B) during maintenance therapy (Mayo endoscopy subscore 2 or 3)